Long-running legal dispute tackles questions of enablement and ‘undue experimentation’ | Federal Circuit says it is bound by SCOTUS’ findings in Amgen v Sanofi.
The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.
Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.
Precedential decision marks blow for medical device maker after earlier win | PTAB criticised for “fundamental legal error” and “narrow definition”.
John Rearick is the latest addition to the firm to strengthen its life sciences practice.
Commission says that medical device maker’s arguments have broad implications for antitrust enforcement | Dispute concerns alleged exclusive-dealing and bundling arrangements.
Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.
Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.
Both drug treatments inhibit a protein called Bruton’s tyrosine kinase that can trigger cancer | Lawsuit comes in wake of patent grant for disputed drug | New study caused headaches for AbbVie’s subsidiary.